News Column

Nuvilex Leverages Expertise to Develop Cannabis-Focused Cancer Treatment

May 21 2013 12:00AM

Marketwire

Tracker

BALTIMORE, MD -- (Marketwired) -- 05/21/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, believes that Nuvilex's diverse expertise could enable the Company to introduce a unique and ground-breaking cancer treatment method. Nuvilex Inc. (OTCQB: NVLX) is an international firm with a live-cell encapsulation technology initially directed to treat pancreatic cancer along with the development and the study of the use of medical marijuana for the treatment of oncology patients.

Nuvilex joins a small number of firms that is studying the prospective medical efficacy of the components of marijuana that have shown medical activity known as "cannabinoids." Nuvilex is building upon the Company's many years of experience in developing "all-natural" products for various uses by studying the medical applications of cannabinoids and developing treatments for serious human diseases. This experience goes a long way in terms of the "man years" spent on natural product-based development by the Company relative to many companies in the industry, and could shorten the time to market.

Importantly, Nuvilex plans to meld its highly regarded live cell-encapsulation technology to treat certain cancers in clinical trials and other tests, with the use of cannabinoids which have demonstrated an ability to act anticancer agents in various studies. Clearly, this live-cell encapsulation technology and cannabinoid combination is both proprietary and unique relative to anything the market has seen to date.

Moreover, it is unlikely that any other Firm will emerge with a similar approach as it would take many years to develop a technology and system even close to the Nuvilex methodology. As a result, if early tests prove successful, this combination should provide the Company with a leg up on other firms in both the traditional oncology and the medical marijuana development spaces.

A copy of this article as well as other articles and Nuvilex reports can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.



Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com





Source: Marketwire


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters